Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 versus placebo with background endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer with bone metastases
NL-OMON44643Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Feb 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in breast cancer, sponsored by Bayer. Started Feb 2016; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON44643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44643.